EN
TÜRKÇE
Oral Presentation - 102
Exploring the Prognostic and Chemotherapy Sensitivity Value of ATG7 in Wilms' Tumor: A Bioinformatics Study
Jizhen Cen
The First Affiliated Hospital of Guangxi Medical University
Wilms' tumor (WT), the most common pediatric malignant kidney tumor, has a treatment controversy regarding the sequence of chemotherapy and surgery. There's an urgent need for biomarkers to evaluate pre - surgical chemotherapy sensitivity. This study aims to explore ATG7's potential as a prognostic and chemotherapy sensitivity marker in WT, offering guidance for treatment strategies.
This study analyzed bulk RNA-sequencing data from 136 WT samples in the TARGET database. The Wilcoxon test was used to compare ATG7 expression differences between WT and adjacent tissues. Kaplan-Meier (KM) analysis with log-rank tests was used for survival analysis. Univariate and multivariate Cox analyses assessed the independent prognostic value of ATG7 expression. The ESTIMATE algorithm calculated tumor microenvironment-related scores, and the single-sample gene set enrichment analysis (ssGSEA) algorithm quantified immune cell infiltration levels. The Genomics of Drug Sensitivity in Cancer (GDSC) database was used to evaluate the sensitivity differences of WT chemotherapeutic drugs (doxorubicin, cisplatin, and vinblastine) between high and low ATG7 expression groups.
ATG7 expression was significantly higher in WT samples than in normal tissues (P < 0.05) and was associated with poor prognosis. KM analysis showed that patients in the high ATG7 expression group had worse survival (P < 0.05). Univariate (P = 0.046, HR = 2.057) and multivariate (P = 0.031, HR = 1.802) Cox analyses confirmed that ATG7 is an independent prognostic factor for WT. GDSC database analysis revealed that patients with high ATG7 expression were more sensitive to doxorubicin (P = 0.00042), cisplatin (P = 0.0083), and vinblastine (P = 0.0025).
ATG7 plays a key role in the prognosis and treatment sensitivity of WT. It has the potential to serve as a prognostic and chemotherapy sensitivity marker, providing a reference for clinical treatment decisions and a new direction for developing optimal treatment strategies.